The objective of the present study was to develop and validate an RP-HPLC method for the quantification of Empagliflozin impurities in a combined pharmaceutical dosage form containing Empagliflozin and Metformin. Chromatographic separation was carried out on an Inertsil ODS C18 column (4.6 × 150 mm, 5 μm) with a flow rate of 1.0 mL/min. The optimized mobile phase consisted of phosphate buffer (pH 3.0) and methanol in a 300:700 (v/v) ratio, with detection performed at 220 nm. The retention times for Empagliflozin Impurity D and Empagliflozin Sugar Dimer Impurity were 5.069 minutes and 9.077 minutes, respectively. Forced degradation studies were performed by subjecting the sample to acidic, alkaline, oxidative, photolytic, and thermal conditions to evaluate degradation impurities. The developed method was statistically validated in accordance with ICH guidelines and proven suitable for routine quality control analysis of Empagliflozin impurities in pharmaceutical formulations.